Epidemiology of Fireworks-Related Injuries to the Upper Extremity in the United States From 2011 to 2017

Abstract

PURPOSE: Fireworks may result in a wide spectrum of injury to the upper extremity ranging from mild burns to amputation. In this cross-sectional study, we describe the epidemiology of upper-extremity injuries in the United States associated with fireworks using the Consumer Product Safety Commission's National Electronic Injury Surveillance System (NEISS). METHODS: The NEISS database was queried between 2011 and 2017 for all injuries of the upper extremity (from shoulder to fingertip) associated with fireworks. There were 806 unique cases, yielding a total weighted estimate of 31,430 national cases presenting to emergency departments in the United States during this time frame. National estimates, standard errors, and 95% confidence intervals were calculated using parameters provided by the NEISS database. Significance of trends was determined using adjusted Wald tests, for which P values less than .05 were considered significant. RESULTS: The weighted estimate was 4,490 yearly cases from 2011 until 2017. Trend analysis did not show a significant change in the number of yearly cases during that time frame. Most injuries (62%) occurred around June 27 until July 11. Nearly 50% of those injured were aged 10 to 29 years and were male. Fireworks with low pyrotechnic content such as sparklers, snakes, and poppers resulted in 26% of injuries. Although 83% of patients were treated and released from the emergency department, other injuries were more severe, with a 4.5% rate of amputation, 7% rate of hospital admission, and 8% rate of transfer to another hospital. CONCLUSIONS: Fireworks injuries to the hand and upper extremity continue to represent a serious burden of disease to the United States population and the health care system. Increased awareness, legislation, and targeted public education about the dangers of fireworks should be considered ways to reduce the incidence of these injuries. TYPE OF STUDY/LEVEL OF EVIDENCE: Prognostic III.